FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced their support to raise awareness of preeclampsia during the third annual National Preeclampsia Awareness Month in May. The Preeclampsia Foundation secured this nationwide designation to educate individuals and organizations about the effects of preeclampsia and the importance of prenatal and postpartum care and education.
Preeclampsia is a leading cause of death in pregnant women. It is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, often the kidneys. It occurs in approximately five to eight percent of all pregnancies and typically occurs after the 20th week of pregnancy. Early onset preeclampsia is a severe form that arises between 23 and 34 weeks gestation. The cause of preeclampsia is unknown, but the number of cases is growing rapidly. At present, delivery of the baby is the only known way to stop the progression of preeclampsia, which without intervention, can escalate to multi-organ failure, seizures, coma or death for the mother and baby.
“Preeclampsia can be devastating and threatens the lives of pregnant women and their babies, yet approaches to treatment have not evolved in decades,” said Robert Greif, Sr. Vice President, rEVO Biologics, Inc. “We are proud to be part of this community as we strive to bring new treatment options for this life threatening condition to these patients.”
“The importance of education cannot be over-estimated,” said Eleni Z. Tsigas, Executive Director of the Preeclampsia Foundation. “Women really need to understand the risk factors for preeclampsia and what it can mean to their pregnancy. We welcome the research and development efforts of rEVO Biologics in our mission to reduce maternal and infant illness and death due to preeclampsia.”
To further research and education in preeclampsia rEVO has provided a multi-year grant of up to $1M to Yale University to establish a Center of Advancement; continues to work with the Preeclampsia Foundation as a member of their Corporate Advisory Council; and is sponsoring the Boston Promise Walk on Saturday, June 27th.
Additionally, in 2014, rEVO initiated the PRESERVE-1 clinical trial. PRESERVE-1 (Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Pre-Eclampsia) is a Phase 3 clinical program for ATryn® [antithrombin (Recombinant)] for the treatment of preeclampsia in pregnant women during the 23rd to 30th week of pregnancy. The goal of the clinical program is to assess if the addition of antithrombin to the current treatment standard, known as "expectant management," can increase the time that the baby stays safely in the womb. For more information about the PRESERVE-1 trial and preeclampsia visit www.PRESERVE-1.org.
About rEVO Biologics
rEVO Biologics, Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. The company’s lead product, ATryn, is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009 for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. The company has a number of products in its pipeline and is actively seeking additional indications for its lead product.
About LFB Group
The LFB Group is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, including hemostasis, immunology and intensive care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and sixth worldwide and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. The LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. To that end, the LFB Group currently markets its products in more than 40 countries around the world with a global turnover of €501.9 million in 2014.